John E. Palardy - Concepedia

Concepedia

Author

John E. Palardy

Memorial Hospital of Rhode Island

Also Known As

JOHN E. PALARDY, John E Palardy, John E. Palardy, John Palardy, John E. Palardy

32

Publications

1.7K

Citations

20

H-Index

56

Concepts

All Affiliations

Memorial Hospital of Rhode Island Brown University Rhode Island Hospital University of Maryland, Baltimore ProThera Biologics (United States)

JE

About

John E. Palardy is an author at Memorial Hospital of Rhode Island specializing in medicine, immunology, and inflammation.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	12	418
2	Health Sciences	1	1	11
3	Allergy	1	1	50
4	Emergency Medicine	1	1	121
5	Endocrinology	1	1	13

John E. Palardy

×

25

Publications

1.7K

Citations

19

H-Index

	Year	Citations
Relationship between Plasma Levels of Lipopolysaccharide (LPS) and LPS‐Binding Protein in Patients with Severe Sepsis and Septic Shock Steven M. Opal, Patrick J. Scannon, Jean‐Louis Vincent, The Journal of Infectious Diseases	1999	605
Inhibition of the RAGE products increases survival in experimental models of severe sepsis and systemic infection Emily Lutterloh, Steven M. Opal, Debra D. Pittman, Critical Care	2007	165
Human neutrophil bactericidal/permeability-increasing protein reduces mortality rate from endotoxin challenge Charles J. Fisher, M N Marra, John E. Palardy, Critical Care Medicine	1994	122
Correlation between Mortality and the Levels of Inter‐Alpha Inhibitors in the Plasma of Patients with Severe Sepsis Yow‐Pin Lim, Steven M. Opal, Edward Siryaporn, The Journal of Infectious Diseases InflammationViral SepsisSevere SepsisInter‐alpha InhibitorsMedicine	2003	121
WAY-202196, a selective estrogen receptor-beta agonist, protects against death in experimental septic shock Patricia Cristofaro, Steven M. Opal, John E. Palardy, Critical Care Medicine	2006	61
Longitudinal studies of inter-alpha inhibitor proteins in severely septic patients: A potential clinical marker and mediator of severe sepsis* Steven M. Opal, Yow‐Pin Lim, Edward Siryaporn, Critical Care Medicine	2007	61
PHARMACOLOGICAL SIRT1 ACTIVATION IMPROVES MORTALITY AND MARKEDLY ALTERS TRANSCRIPTIONAL PROFILES THAT ACCOMPANY EXPERIMENTAL SEPSIS Steven M. Opal, James L. Ellis, Vipin Suri, Shock InflammationCytokineAllergyAntibioticsLung Inflammation	2015	50
A Monoclonal Antibody Against RAGE Alters Gene Expression and is Protective in Experimental Models of Sepsis and Pneumococcal Pneumonia Eirini Christaki, Steven M. Opal, James C. Keith, Shock InflammationPsychoneuroimmunologyLung InflammationHumoral ResponseImmunology	2011	49
Active Immunization with a Detoxified<i>Escherichia coli</i>J5 Lipopolysaccharide Group B Meningococcal Outer Membrane Protein Complex Vaccine Protects Animals from Experimental Sepsis Alan S. Cross, Steven M. Opal, H. Shaw Warren, The Journal of Infectious Diseases	2001	43
Inter-Alpha-Inhibitor Proteins Are Endogenous Furin Inhibitors and Provide Protection against Experimental Anthrax Intoxication Steven M. Opal, Andrew W. Artenstein, Patricia Cristofaro, Infection and Immunity ImmunotoxicologyImmunologyCell DeathPharmacotherapyAntimicrobial Chemotherapy	2005	42

Page 1